| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H20N2O3S2 |
| Molecular Weight | 340.461 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(NC(=S)[C@H](CSC)N2C(=O)OC(C)C)C=C1
InChI
InChIKey=GWKIPRVERALPRD-ZDUSSCGKSA-N
InChI=1S/C15H20N2O3S2/c1-9(2)20-15(18)17-12-7-10(19-3)5-6-11(12)16-14(21)13(17)8-22-4/h5-7,9,13H,8H2,1-4H3,(H,16,21)/t13-/m0/s1
| Molecular Formula | C15H20N2O3S2 |
| Molecular Weight | 340.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Talviraline (HBY 097) was developed as a nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (NNRTI) for the treatment of HIV Infections. Talviraline participated in a phase II clinical trial. It was found that the drug caused pronounced acute suppression of HIV-1 replication both in combination with zidovudine and alone. However, further development of the drug has been discontinued.
Approval Year
PubMed
|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
TARGET -> INHIBITOR |
|
Showing 1 to 2 of 2 entries
